Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 5, Issue 4, 2006, Pages 237-244

  Lebecque, Patrick ^a   Leal, Teresinha ^a   Zylberberg, Katia ^a   Reychler, Grégory ^a   Bossuyt, Xavier ^b   Godding, Véronique ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cystic fibrosis; Inhaled antibiotics; Prophylaxis; Pseudomonas

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; COLISTIN; SALBUTAMOL; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BELGIUM; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG INTERMITTENT THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HEALTH CARE POLICY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCRIPTION; PREVALENCE; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REGISTER; RESPIRATORY TRACT INFECTION; SERODIAGNOSIS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; CHILD; CHRONIC DISEASE; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; TOBRAMYCIN;

EID: 34147189596     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2006.04.001     Document Type: Article

References (55)

1. In: Bauernfeind A., Marks M.I., and Strandvik B. (Eds). Cystic fibrosis pulmonary infections: lessons from around the world (1996), Birkhauser Verlag, Basel
2. Taylor R.F., and Hodson M.E. Cystic fibrosis prescribing practices in the United Kingdom and Eire. Respir Med 87 (1993) 535-539
3. Döring G., and Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 3 (2004) 67-91
4. Belgisch Mucoviscidose Register - Registre Belge de la Mucoviscidose - 1999, 2000, 2001, 2002. Annual Data Report, Belgium.
5. Rosenstein B.J., and Cutting G.R. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132 (1998) 589-595
6. Döring G., Conway S., Heijerman H., Hodson M., Høiby N., Smyth A., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16 (2000) 749-767
7. Cystic Fibrosis Trust. Report of the UK Cystic Fibrosis Trust Antibiotic Group. 2002.
8. Knudson R., Lebowitz M., Holberg C., and Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127 (1983) 725-734
9. Subbarao P., Lebecque P., Corey M., and Coates A.L. Comparison of spirometric reference values. Pediatr Pulmonol 37 (2004) 515-522
10. Lee T., Brownlee K., Conway S., Denton M., and Littlewood J. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2 (2003) 29-34
11. Pedersen S.S., Espersen F., and Hoiby N. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol 25 10 (1987 (Oct.)) 1830-1836
12. Proesmans M., Balinska-Miskiewicz W., Dupont L., Bossuyt X., Verhaegen J., and De Boeck K. Lee's criteria for chronic Pseudomonas aeruginosa infection in a Belgian paediatric and adult cysric fibrosis centre. J Cyst Fibros 4 (2005) S40 [abstract]
13. Mac Lusky I., Gold R., Corey M., and Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 7 (1989) 42-48
14. Sens B, Stern M, Wiedemann B. Qualitätssicherung Mukoviszidose. Überblick ûber den Gesundheitszustand der Patienten in Deutschland 1999. Zentrum fûr Qualitätsmanagement im Gesundheitswesen. Germany. Hannover, 2000.
15. Tacetti G., and Campana S. Microbiologic data overview of Italian cystic fibrosis patients. Eur J Epidemiol 13 (1997) 323-327
16. Cystic Fibrosis Foundation Patient Registry. Annual data report (2001), Cystic Fibrosis Foundation, Bethesda (MD), USA
17. Cystic Fibrosis Foundation Patient Registry. Annual data report (2002), Cystic Fibrosis Foundation, Bethesda (MD), USA
18. Lee T., Brownlee K., Denton M., Littlewood J., and Conway S. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional paediatric cystic fibrosis centre. Pediatr Pulmonol 37 (2004) 104-110
19. Kerem E., Corey M., Gold R., and Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 116 (1990) 714-719
20. Pamukcu A., Bush A., and Buchdahl R. Effects of Pseudomonas aeruginosa colonisation on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 19 (1995) 10-15
21. Kosorok M., Zeng L., West S., Rock M., Splaingard M., Laxova A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 32 (2001) 277-287
22. Emerson J., Rosenfeld M., Mc Namara S., Ramsey B., and Gibson R. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34 (2002) 91-100
23. Cystic Fibrosis Foundation, Patient Registry 1996 Annual Data Report, Bethesda, Maryland, August 1997.
24. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 34 (2002) 232-236
25. Baumann U., Stocklossa C., Greiner W., von der Schulenburg J.M., and von der Hardt H. Cost of the care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2 (2003) 84-90
26. Littlewood J.M., Miller M.G., Ghoneim A.G., and Ramsden C.H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet i (1985) 865
27. Valerius N., Koch C., and Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation by early treatment. Lancet 338 (1991) 725-726
28. Frederiksen B., Koch C., and Hoiby N. Antibiotic treatment at time of initial colonisation with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration in pulmonary function in patients with cystic fibrosis. Pediatr Pulmonol 23 (1997) 330-335
29. Wiesemann H., Steinkamp G., Ratjen F., Bauernfeind A., Przyklenk B., Doring G., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25 (1998) 88-92
30. Ratjen F., Döring G., and Nikolaizik W. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358 (2001) 983-984
31. Tacetti G., Repetto T., Procopio E., Farina S., and Campana S. Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients. Lancet 359 (2002) 625-626 [letter]
32. Munck A., Bonacorsi S., Mariani-Kurkdjian P., Lebourgeois M., Gerardin M., Brahimi N., et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 32 (2001) 288-292
33. Heinzl B., Eber E., Oberwaldner B., Haas G., and Zach M. Effects of inhaled gentamycin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 33 (2002) 32-37
34. Frederiksen B., Koch C., and Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 28 (1999) 159-166
35. Schechter M., Shelton B., Margolis P., and Fitzsimmons S. The association of socio-economic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 163 (2001) 1331-1337
36. Lebecque P., Leal T., De Boeck C., Jaspers M., Cuppens H., and Cassiman J. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am J Respir Crit Care Med 165 (2002) 757-761
37. Leal T., Lebacq J., Lebecque P., Cumps J., and Wallemacq P. Modified method to measure nasal potential difference. Clin Chem Lab Med 41 (2003) 61-67
38. Koch C., Cuppens H., Rainisio M., Madessani U., Harms H., Hodson M., et al. Investigators of the ERCF. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 31 (2001) 1-12
39. Kosorok M., Jaladuddin M., Farrell P., Shen G., Colby C., Laxova A., et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol 26 (1998) 81-88
40. Kerem E., Corey M., Stein R., Gold R., and Levison H. Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients. Pediatr Infect Dis J 9 (1990) 494-498
41. Maselli J., Sontag M., Norris J., Wagener J., and Accurso F. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol 35 (2003) 257-262
42. West E., Zeng L., Lee B., Kosorok M., Laxova A., Rock M., et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis. Early detection by serology and assessment of risk factors. JAMA 287 (2002) 2958-2967
43. Johansen H., and Høiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 47 (1992) 109-111
44. Pai V.B., and Nahata M.C. Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr Pulmonol 32 (2001) 314-327
45. Burns J.L., Gibson R., Mc Namara S., Yim D., Emerson J., Rosenfeld M., et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 183 (2001) 444-452
46. Armstrong D., Grimwood K., Carlin J.B., Carzino R., Olinsky A., and Phelan P.D. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 21 (1996) 267-275
47. Anhoj J., Thorsson L., and Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crit Care Med 162 (2000) 1819-1822
48. Coates A.L., and Ho S.L. Drug administration by jet nebulization. Pediatr Pulmonol 26 (1998) 412-423
49. Coates A.L., Dinh L., MacNeish C.F., Rollin T., Gagnon S., Ho S.L., et al. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 13 (2000) 169-178
50. Leung K., Louca E., and Coates A.L. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest 126 (2004) 1619-1627
51. Hoiby N., Frederiksen B., and Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 4 (2005) 49-54
52. Schidlow D.V. Something is (not) rotten in Denmark [Hamlet (not) W. Shakespeare]. Pediatr Pulmonol 23 (1997) 325-326
53. Nixon G.M., Armstrong D.S., Carzino R., Carlin J.B., Olinsky A., Robertson C.F., et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 138 (2001) 699-704
54. Rosenfeld M., Gibson R.L., McNamara S., Emerson J., Burns J.L., Castile R., et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 32 (2001) 356-366
55. Burns J.L., Van Dalfsen J.M., Shawar R.M., Otto K.L., Garber R.L., Quan J.M., et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179 (1999) 1190-1196